#USA #Clinical Trials #Leesburg #Resonant Solutions #Creapharm Bioservices

Enhancing Clinical Support: Resonant Clinical Solutions Acquires Creapharm Bioservices

In a strategic move reminiscent of some of the most notable acquisitions in health tech, Resonant Clinical Solutions has made headlines with its acquisition of Creapharm Bioservices, a prominent player in biobanking and cryogenic storage located in France. This acquisition not only marks a significant growth spurt for Resonant, but it also highlights a growing trend within the life sciences sector toward specialized clinical solutions aimed at supporting increasingly complex therapeutic programs.

Strengthening Biorepository Services

Founded with the mission to provide integrated clinical solutions targeted at life sciences organizations, Resonant has emerged as a key partner in managing the clinical supply chain and sample lifecycle. By acquiring Creapharm, the firm amplifies its existing biorepository capabilities, signaling its commitment to maintaining its competitive edge in a rapidly evolving industry.

Creapharm, based in Bailly-Romainvilliers, France, is well-known for its specialized offerings in cryogenic storage required for biotherapeutics, specifically for Advanced Therapy Medicinal Products (ATMPs) and other sensitive biological samples. The technology and practices at Creapharm enable vapor-phase nitrogen storage at temperatures as extreme as -196°C, adopting rigorously adhered-to standards such as Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP).

Meeting Industry Demands

The acquisition comes amid growing industry demands for expertise in the management of advanced therapies. A recent report by IQVIA noted a significant rise in non-small-molecule assets entering clinical trials, which now account for 46% of Phase I–III starts. This trend underscores an urgent need for solutions that support clinical pipelines pivoting toward specialized modalities.

Christophe Berthoux, CEO of Resonant Clinical Solutions, emphasized the increasing complexity faced by life sciences companies, stating, "As clinical pipelines become more specialized, our partners need our extensive expertise and infrastructure to navigate the intricacies involved in clinical trials. The acquisition of Creapharm solidifies our position to support our customers developing advanced and sensitive therapies effectively."

Benefits of the Acquisition

The addition of Creapharm Bioservices to Resonant's operations ensures:

• - Enhanced Cryogenic Storage: With temperatures managed from -196°C to -20°C, the facility can adapt to the stringent requirements of advanced therapies.
• - Comprehensive Chain-of-Custody: Integrity of samples is safeguarded, from controlled room temperatures to cryogenic conditions, ensuring reliability of storage solutions.
• - Expertise: The transition adds exceptional knowledge for managing biotherapeutics and advanced therapies, allowing for more nuanced service offerings.
• - GMP/GDP Compliance: Aligning with regulatory frameworks enhances the credibility and reliability of the services provided.

This expansion into the European market will also bolster Resonant's existing customer relationships and infrastructure footprint, which is crucial for a company navigating the challenges of clinical trials.

Future Directions

Greg Lavin, CEO of Myonex (Creapharm’s parent company before the acquisition) expressed enthusiasm about the transaction, viewing it as a strategic alignment that allows Myonex to focus on its core strengths while enabling Creapharm to thrive under Resonant’s broader operational umbrella.

With this acquisition, Resonant has set a robust foundation to continue its mission of empowering life sciences organizations. By alleviating the complexities of trial management and sample preservation, Resonant contributes directly to advancing the healthcare landscape—a vital step in improving patient outcomes globally.

As Resonant begins to integrate Creapharm into its operations, the future looks promising for both firms as they venture into a new era of clinical prowess that prioritizes innovation and specialized support in the realm of healthcare.